Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Abstract Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogen...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Han-Chung Lee, Hamizun Hamzah, Melody Pui-Yee Leong, Hadri Md Yusof, Omar Habib, Shahidee Zainal Abidin, Eryse Amira Seth, Siong-Meng Lim, Sharmili Vidyadaran, Mohamad Aris Mohd Moklas, Maizaton Atmadini Abdullah, Norshariza Nordin, Zurina Hassan, Pike-See Cheah, King-Hwa Ling
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/b2cbcfa33d8b42fb93d9fbc95b27e345
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares